Uncategorized

Saphetor Partners with ICON to Develop Innovative Data-centric Approach to Precision Medicine Clinical Trial Strategies to Help Support Unique Patients

Saphetor SA announce that it is partnering with world-leading healthcare intelligence and clinical research organisation ICON to develop an innovative approach to support the planning and execution of clinical trials in the precision medicine and rare diseases space.

Saphetor Partners with ICON to Develop Innovative Data-centric Approach to Precision Medicine Clinical Trial Strategies to Help Support Unique Patients Read More »

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

Teva Pharmaceutical Industries Ltd. announce that data from the UNITE study presented at the World Congress of Neurology in Montreal, Canada, show that AJOVY® reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder.

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder Read More »

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

Hansa Biopharma announced results from an extended pooled analysis using data from the 17-HMedIdeS-14 study,1 an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase, showing sustained positive outcomes out to 5 years in the majority of highly sensitized patients who received an imlifidase-enabled kidney transplant.

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study Read More »

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

WuXi Biologics announced that it has launched a new proprietary bioprocessing platform WuXiUI™, an ultra-intensified, fed-batch solution that enhances the productivity and quality of multiple different CHO or other mammalian cell lines and product modalities.

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality Read More »

Scroll to Top